File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant

TitleEfficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant
Authors
Issue Date2002
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com
Citation
Transplantation, 2002, v. 73 n. 1, p. 148-151 How to Cite?
AbstractReactivation of chronic hepatitis B virus (HBV) infection is a major cause of morbidity and mortality after renal transplantation. Although lamivudine is an effective treatment for chronic hepatitis B, the development of drug resistance due to mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) motif is a major concern, especially in immunosuppressed patients who require prolonged therapy. Treatment with famciclovir has not been effective in the majority of patients who developed lamivudine resistance due to methionine-to-valine mutation at position 550, because this mutation has been uniformly associated with leucine-to-methionine mutation at position 526, a mutation that is associated with resistance to famciclovir. We describe a renal transplant recipient with an uncommon lamivudine-resistant HBV variant, in which methionine-to-valine/isoleucine mutation at position 550 was associated with wild-type sequence at position 526. The severe hepatitic flare consequent to the lamivudine resistance in this patient was successfully treated with famciclovir, indicating that both M550V and M550I mutants with preserved wild-type sequence at position 526 of HBV reverse transcriptase are susceptible to famciclovir. Our experience shows that famciclovir can be useful in selected patients with otherwise potentially fatal hepatitic flares related to lamivudine resistance, and that analysis of mutations in the HBV variant can be helpful in the choice of antiviral therapy.
Persistent Identifierhttp://hdl.handle.net/10722/77804
ISSN
2015 Impact Factor: 3.69
2015 SCImago Journal Rankings: 1.699
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, Sen_HK
dc.contributor.authorHo, SKNen_HK
dc.contributor.authorMoniri, Ken_HK
dc.contributor.authorLai, KNen_HK
dc.contributor.authorChan, TMen_HK
dc.date.accessioned2010-09-06T07:35:55Z-
dc.date.available2010-09-06T07:35:55Z-
dc.date.issued2002en_HK
dc.identifier.citationTransplantation, 2002, v. 73 n. 1, p. 148-151en_HK
dc.identifier.issn0041-1337en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77804-
dc.description.abstractReactivation of chronic hepatitis B virus (HBV) infection is a major cause of morbidity and mortality after renal transplantation. Although lamivudine is an effective treatment for chronic hepatitis B, the development of drug resistance due to mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) motif is a major concern, especially in immunosuppressed patients who require prolonged therapy. Treatment with famciclovir has not been effective in the majority of patients who developed lamivudine resistance due to methionine-to-valine mutation at position 550, because this mutation has been uniformly associated with leucine-to-methionine mutation at position 526, a mutation that is associated with resistance to famciclovir. We describe a renal transplant recipient with an uncommon lamivudine-resistant HBV variant, in which methionine-to-valine/isoleucine mutation at position 550 was associated with wild-type sequence at position 526. The severe hepatitic flare consequent to the lamivudine resistance in this patient was successfully treated with famciclovir, indicating that both M550V and M550I mutants with preserved wild-type sequence at position 526 of HBV reverse transcriptase are susceptible to famciclovir. Our experience shows that famciclovir can be useful in selected patients with otherwise potentially fatal hepatitic flares related to lamivudine resistance, and that analysis of mutations in the HBV variant can be helpful in the choice of antiviral therapy.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.comen_HK
dc.relation.ispartofTransplantationen_HK
dc.rightsTransplantation. Copyright © Lippincott Williams & Wilkins.en_HK
dc.subject.mesh2-Aminopurine - analogs & derivatives - therapeutic useen_HK
dc.subject.meshAdulten_HK
dc.subject.meshDNA, Viral - genetics - isolation & purificationen_HK
dc.subject.meshDrug Resistance, Microbialen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHepatitis B - drug therapyen_HK
dc.subject.meshHepatitis B virus - drug effects - genetics - isolation & purificationen_HK
dc.subject.meshHumansen_HK
dc.subject.meshKidney Failure, Chronic - surgeryen_HK
dc.subject.meshKidney Transplantation - physiologyen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshMutationen_HK
dc.subject.meshPostoperative Complications - virologyen_HK
dc.titleEfficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutanten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0041-1337&volume=73&issue=1&spage=148&epage=151&date=2001&atitle=Efficacy+of+famciclovir+in+the+treatment+of+lamivudine+resistance+related+to+an+atypical+hepatitis+B+virus+mutanten_HK
dc.identifier.emailTang, S: scwtang@hku.hken_HK
dc.identifier.emailNeng Lai, K: knlai@hku.hken_HK
dc.identifier.emailMao Chan, T: dtmchan@hku.hken_HK
dc.identifier.authorityTang, S=rp00480en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid11792996-
dc.identifier.scopuseid_2-s2.0-0037080758en_HK
dc.identifier.hkuros67224en_HK
dc.identifier.hkuros69577-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037080758&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume73en_HK
dc.identifier.issue1en_HK
dc.identifier.spage148en_HK
dc.identifier.epage151en_HK
dc.identifier.isiWOS:000173484500028-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTang, S=7403437082en_HK
dc.identifier.scopusauthoridN Ho, SK=18040480100en_HK
dc.identifier.scopusauthoridMoniri, K=36963023200en_HK
dc.identifier.scopusauthoridNeng Lai, K=7402135706en_HK
dc.identifier.scopusauthoridMao Chan, T=7402687700en_HK
dc.customcontrol.immutablejt 130423-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats